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Plasma androgen receptor and 
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Delia De Lisi5, Salvatore Luca Burgio1, Himisha Beltran6, Gerhardt Attard2,7 & Ugo De Giorgi1
Recently, mixed forms between adenocarcinoma and neuroendocrine prostate cancer (NEPC) 
have emerged that are characterized by persistent androgen receptor (AR)-signalling and elevated 
chromogranin A (CgA) levels. The main aim of this study was to analyze castration-resistant prostate 
cancer (CRPC) patients treated with abiraterone or enzalutamide, assessing progression-free/
overall survival (PFS/OS) in association with circulating AR and CgA. AR aberrations were analyzed 
by droplet digital PCR in pre-treatment plasma samples collected from two biomarker protocols [197 
patients from a retrospective study (REC 2192/2013) and 59 from a prospective trial (REC 6798/2015)]. 
We subdivided patients into three groups according to CgA by receiver-operating characteristic (ROC) 
curves. In the primary cohort, plasma AR gain and mutations (p.L702H/p.T878A) were detected in 78 
(39.6%) and 16 (8.1%) patients, respectively. We observed a significantly worse PFS/OS in patients with 
higher-CgA than in patients with normal-CgA, especially those with no AR-aberrations. Multivariable 
analysis showed AR gain, higher-CgA and LDH levels as independent predictors of PFS [hazard ratio 
(HR) = 2.16, 95% confidence interval (95% CI) 1.50–3.12, p < 0.0001, HR = 1.73, 95% CI 1.06–2.84, 
p = 0.026, and HR = 2.13, 95% CI 1.45–3.13, p = 0.0001, respectively) and OS (HR = 1.72, 95% CI 1.15–
2.57, p = 0.008, HR = 3.63, 95% CI 2.13–6.20, p < 0.0001, and HR = 2.31, 95% CI 1.54–3.48, p < 0.0001, 
respectively). These data were confirmed in the secondary cohort. Pre-treatment CgA detection could 
be useful to identify these mixed tumors and would seem to have a prognostic role, especially in AR-
normal patients. This association needs further evaluation in larger prospective cohorts.
Prostate cancer is the most commonly diagnosed cancer in men worldwide and a major cause of cancer death1. 
After an initial response to medical or surgical castration, the disease will progress to castration-resistant prostate 
cancer (CRPC)2. Many drugs with different mechanisms of action are currently available for CRPC patients and 
have led to a significant benefit in survival3–8. However, the identification of predictive factors could help clini-
cians to better select the next-line systemic therapy on the basis of molecular risk stratification. The implemen-
tation of these biomarkers in routine clinical practice would substantially facilitate patient-tailored treatment.
The molecular landscape of CRPC provides insights into the mechanisms of tumor heterogeneity and treat-
ment resistance9–11. Resistance in CRPC is typically driven by the reactivation of androgen receptor (AR) signal-
ling, occuring through AR splice variants (such as AR-V7), and AR point mutations or amplification, which can 
be detected in blood12–20. In recent years, cell-free DNA has emerged as a promising and non-invasive biomarker 
for the characterization of the tumor genome21. Approximately 3% of tumor DNA is released into the blood daily, 
most likely deriving from apoptosis/necrosis of malignant cells22. High levels of cell-free DNA (4- to 6-fold that 
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of healthy controls) have been detected in patients with tumors, including prostate cancer22. Recently, AR gene 
aberrations detected in cell-free DNA of CRPC patients using PCR-based methods or next generation sequencing 
have been associated with worse outcome and resistance to abiraterone and enzalutamide, suggesting a potential 
predictive/prognostic role for plasma AR status12–17.
In CRPC, neuroendocrine differentiation (NED) represents an alternative AR-independent mechanism 
of resistance to cancer therapeutics, especially androgen deprivation agents. Neuroendocrine prostate cancer 
(NEPC) is uncommon and characterized by decreased prostate specific antigen (PSA) secretion, and usually by 
the expression of neuroendocrine markers, such as chromogranin A (CgA), synaptophysin, and neuron spe-
cific enolase (NSE)23,24. In addition, NEPC usually shows loss of AR expression and suppressed AR signalling, 
while AR aberrations (point mutation and gain) are present at low levels, probably because of clonal selection of 
non-amplified prostate adenocarcinoma subpopulations through selective pressure, especially during anti-AR 
therapies24. De novo small-cell prostate cancer, a highly aggressive histologic variant, is present in <1% of 
untreated prostate cancers, whereas the frequency of treatment-related NEPC has been reported as occurring 
in up to 20% of patients during the course of CRPC progression23–25. A recent classification of neuroendocrine 
prostatic tumors26 showed variants of neuroendocrine prostate cancer, including a mixed form between NEPC 
and conventional adenocarcinoma, usually characterized by AR independence, However, mixed tumors have 
been also observed with both AR positive and AR negative cells and, on occasion, with dual expression of both 
neuroendocrine markers and AR in the same tumor cells due to inter- and intra-patient clinical and pathologic 
heterogeneity. Consequently, a more accurate clinical and molecular classification is needed for these overlapping 
clinical entities, and further research is warranted to identify their prognostic impact27.
In addition, elevated levels of serum CgA, commonly observed in NEPC, may increase in CRPC patients with 
adenocarcinoma histology28 who show a shorter survival than those with normal CgA values29,30.
Our main objective was to identify the correlation between AR status and CgA level before the administra-
tion of anti-AR therapies and in different settings (chemotherapy-naïve and chemotherapy-treated patients) in 
prostate adenocarcinoma. We also evaluated the impact on treatment outcome of CgA levels in association with 
cell-free AR status.
Results
Overall patient characteristics. The primary cohort included 197 patients from a retrospective biomarker 
study (REC 2192/2013) and the secondary cohort consisted of 59 from a prospective biomarker trial (REC 
6798/2015). Patients with available pre-treatment serum CgA and plasma DNA for detection of AR gene aberra-
tion were considered evaluable. All patients in both cohorts underwent prostate biopsy and/or prostatectomy at 
diagnosis with a confirmed histology of prostate adenocarcinoma without NED. Median age was 73 years (range, 
42–91) and 75 (range, 48–89) in the primary and secondary cohorts, respectively. The prospective biomarker 
trial was more recent than retrospective study and, consequently, included many more chemotherapy-naïve cases 
treated with abiraterone or enzalutamide (N = 38, 64.4%) than the retrospective study (N = 40, 20.3%). This sub-
stantial difference may justify the different baseline characteristics between the two cohorts (e.g., presence of 
visceral metastases and number of previous treatments).
The median serum CgA level was 122 ng/mL (range, 10–1000) (normal CgA value < 120 ng/mL). However, 
the receiver-operating characteristic (ROC) analysis, one of the most commonly used methods to analyze the 
effectiveness of a diagnostic, was used to evaluate the role of pre-treatment serum CgA for assessing the response 
to no response to treatment with abiraterone or enzalutamide. The cutoffs for CgA in response to AR-directed 
therapies were calculated through the area under the ROC curve (AUC), as previously reported29,30. In the pri-
mary cohort, serum CgA level was considered normal in 92 (46.7%) patients, elevated but ≤ 3-fold the upper nor-
mal value (UNV) in 66 (33.5%) and ≥3-fold the UNV in 39 (20.3%) patients. A similar distribution of CgA levels 
was observed in the secondary cohort. We assessed AR status in cell-free DNA showing AR copy number (CN) 
gain in 78 (39.6%) and AR mutations (p.L702H or p.T878A) in 16 (8.1%) patients of the primary cohort. In the 
secondary cohort, plasma AR gain and mutations were reported in 11 (18.6%) and 2 (3.4%) patients, respectively. 
All patient characteristics are summarized in Table 1.
Association between baseline cell-free AR aberrations and serum CgA. No significant differences 
were observed in either cohort between cell-free AR status and CgA measurements, with the exception of a trend 
(p = 0.057) of higher CgA level in AR-gained chemotherapy-naïve patients of the secondary cohort (Table 2). 
Using a different cut-off for CgA levels, we observed concordant results showing no correlation between AR status 
and serum CgA concentration (Supplementary Table S1).
Combination of AR status with CgA levels and PSA response. Median baseline PSA was 44.5 ng/
mL (range, 1.48–4351), and our results did not reveal a significant difference between PSA and CgA levels 
(Supplementary Table S2) (as commonly shown in NEPC)24,30.
No association was seen between PSA response and CgA levels according to cell-free AR copy number (CN) 
in the primary and secondary cohort (Supplementary Table S3).
Combination of AR status with CgA levels and survival. The median follow-up of patients from the 
primary and secondary cohort was 32.4 months (range, 1–73) and 17.6 months (range, 1–49), respectively.
We did not evaluate the impact of AR mutations on treatment outcome because cell-free AR mutations were 
uncommon, especially in chemotherapy-naïve patients, as shown in previous studies10,12,13, and the clinical rele-
vance of rarer mutations is uncertain. Our droplet digital PCR (ddPCR) assay detected point mutations present 
in at least 2% of plasma DNA.
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In both cohorts, we observed a significant association between worse progression-free/overall survival (PFS/
OS) and elevated CgA levels in AR-normal patients treated with abiraterone or enzalutamide, more evident 
in post-docetaxel setting for the primary cohort or in pre-docetaxel for the secondary cohort (Figs 1 and 2; 
Supplementary Tables S4 and S5).












docetaxel (n = 38)
Abi/Enza post-
docetaxel (n = 21)
n (%) n (%) n (%) n (%) n (%) n (%)
Age, years median value 
(range) 73 (42–91) 72 (59–89) 73 (42–91) 75 (48–89) 75 (48–89) 76 (64–86)
Gleason score
6–7 73 (41.5) 18 (51.4) 55 (39.0) 19 (39.6) 13 (41.9) 6 (35.3)
8–10 103 (58.5) 17 (48.6) 86 (61.0) 29 (60.4) 18 (58.1) 11 (64.7)
Unknown/missing 21 5 16 11 7 4
Metastastic sites
No visceral 162 (82.6) 39 (97.5) 123 (78.8) 58 (98.3) 37 (97.4) 21 (100)
Visceral 34 (17.4) 1 (2.5) 33 (21.1) 1 (1.7) 1 (2.6) 0
Unknown 1 0 1 0 0 0
Lines of previous treatments
≤2 122 (61.9) 40 (100) 82 (52.2) 51 (86.4) 37 (97.4) 14 (66.7)
>2 75 (38.1) 0 75 (47.8) 8 (13.6) 1 (2.6) 7 (33.3)
Previous abi or enza treatment
No 147 (74.6) 36 (90.0) 111 (70.7) 54 (91.5) 36 (94.7) 18 (85.7)
Yes 50 (25.4) 4 (10.0) 46 (29.3) 5 (8.5) 2 (5.3) 3 (14.3)
ECOG
0–1 180 (91.4) 39 (97.5) 141 (89.8) 56 (94.9) 35 (92.1) 21 (100)
≥2 17 (8.6) 1 (2.5) 16 (10.2) 3 (5.1) 3 (7.9) 0
AR copy number
Normal 119 (60.4) 29 (72.5) 90 (57.3) 48 (81.4) 32 (84.2) 16 (76.2)
Gain 78 (39.6) 11 (27.5) 67 (42.7) 11 (18.6) 6 (15.8) 5 (23.8)
AR mutations
No 181 (91.9) 38 (95.0) 143 (91.1) 57 (96.6) 37 (97.4) 20 (95.2)
Yes 16 (8.1) 2 (5.0) 14 (8.9) 2 (3.4) 1 (2.6) 1 (4.8)
CgA, ng/mL
<120 92 (46.7) 33 (82.5) 59 (37.6) 30 (50.9) 20 (52.6) 10 (47.6)
120–360 66 (33.5) 6 (15.0) 60 (38.2) 18 (30.5) 12 (31.6) 6 (28.6)
>360 39 (19.8) 1 (2.5) 38 (24.2) 11 (18.6) 6 (15.8) 5 (23.8)
Baseline ALP, U/L median 
value (range)
112 
(35–1345) 97 (44–310) 120 (35–1345)
110 
(12–321) 110 (12–321) 116 (40–259)
<129 83 (56.5) 20 (66.7) 63 (53.8) 22 (66.7) 16 (69.6) 6 (60.0)
≥129 64 (43.5) 10 (33.3) 54 (46.2) 11 (33.3) 7 (30.4) 4 (40.0)
Unknown 50 10 40 26 15 11
Baseline LDH, U/L median 
value (range)
186 
(67–1808) 156 (67–711) 194 (97–1808)
179 
(88–695) 176 (88–675) 199 (98–695)
<225 116 (72.0) 33 (86.8) 83 (67.5) 41 (85.4) 431 (91.2) 10 (71.4)
≥225 45 (28.0) 5 (13.2) 40 (32.5) 7 (14.6) 3 (8.8) 4 (28.6)
Unknown 36 2 34 11 4 7
Baseline NLR
<3 104 (58.1) 20 (55.6) 84 (58.7) 19 (48.7) 14 (50.0) 5 (45.5)
≥3 75 (41.9) 16 (44.4) 59 (41.3) 20 (51.3) 14 (50.0) 6 (54.5)
Unknown/missing 18 4 14 20 10 10
Baseline Hb, g/dL median 
value (range) 12 (7–15.5) 13.1 (10.2–15.5) 11.8 (7.0–15.1)
12.2 
(10.8–101) 12.3 (10.8–101) 12 (11–13)







4294) 27.02 (1.48–429) 17.39 (3.80–1899)
Table 1. Patient characteristics in the Primary and Secondary Cohort. Abbreviations. Abi, abirtaerone; ALP, 
alkaline phosphatase; AR, androgen receptor; CgA, chromogranin A; ECOG, Eastern Cooperative Oncology 
Group; enza, enzalutamide; Hb, haemoglobin; LDH, lactate dehydrogenase; n, number; NLR, neutrophil to 
lymphocyte ratio; PLR, platelets to lymphocyte ratio; PSA, prostate-specific antigen.
www.nature.com/scientificreports/
4Scientific RePoRtS |  (2018) 8:15442  | DOI:10.1038/s41598-018-33774-4
Multivariable analysis revealed AR gain and higher CgA and lactate dehydrogenase (LDH) levels as an inde-
pendent predictors of PFS [hazard ratio (HR) 2.16, 95% confidence interval (CI) 1.50–3.12, p < 0.0001, HR 1.73, 
95% CI 1.06–2.84, p = 0.026, and HR 2.13, 95% CI 1.45–3.13, p = 0.0001, respectively) and OS (HR 1.72, 95% CI 
1.15–2.57, p = 0.008, HR 3.63, 95% CI 2.13–6.20, p < 0.0001, and HR 2.31, 95% CI 1.54–3.48, p < 0.0001, respec-
tively) (Supplementary Table S6). In the secondary cohort, higher CgA concentration was confirmed as inde-
pendent predictors of PFS and OS (HR 4.16, 95% CI 1.51–11.49, p = 0.006 and HR 62.97, 95% CI 5.08–781.12, 
p = 0.001, respectively), together with AR gain and elevated LDH level.
In overall patient population, interactions between treatment (abiraterone versus enzalutamide) and AR status 
examined in the Cox models were not significant (p = 0.131 for PFS and p = 0.598 for OS).
Primary cohort Secondary cohort








(n = 11) p No (n = 57) Yes (n = 2) p
Abi/Enza pre-docetaxel, n (%)
CgA <120 25 (86.2) 8 (72.7) 31 (81.6) 2 (100.0) 19 (59.4) 1 (16.7) 20 (54.1) 0 (0)
120–360 3 (10.3) 3 (27.3) 6 (15.8) 0 (0) 9 (28.1) 3 (50.0) 12 (32.4) 0 (0)
>360 1 (3.5) 0 (0) 0.542 1 (2.6) 0 (0) 0.532 4 (12.5) 2 (33.3) 0.057 5 (13.5) 1 (100) 0.065
Abi/Enza post-docetaxel, n (%)
CgA <120 35 (38.9) 24 (35.8) 55 (38.5) 4 (28.6) 7 (43.7) 3 (60.0) 10 (50.0) 0 (0)
120–360 39 (43.3) 21 (31.3) 55 (38.5) 5 (35.7) 4 (25.0) 2 (40.0) 5 (25.0) 1 (100)
>360 16 (17.8) 22 (32.9) 0.148 33 (23.1) 5 (35.7) 0.300 5 (31.3) 0 (0) 0.264 5 (25.0) 0 (0) 0.769
Table 2. Association between baseline cell-free AR aberrations and serum CgA in the Primary and Secondary 
cohort. Abbreviations. Abi, abiraterone; AR, androgen receptor; CgA, chromogranin A; enza, enzalutamide; n, 
number; UNV, upper normal value.
Figure 1. Survival in patients treated with abiraterone or enzalutamide by AR status and CgA levels in the 
Primary cohort. PFS (A) and OS (B) in AR-normal and PFS (C) and OS (D) in AR-gained patients according to 
three different CgA level groups. The blue line is for patients with serum CgA <120 ng/mL, the orange line for 
CgA between 120 and 360 ng/mL, and the green line for CgA level >360 ng/mL.
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Discussion
The growing use of AR-directed agents and a higher number of biopsies performed not only at diagnosis, but 
also at different time points during the course of prostate cancer are leading to an increased detection of NEPCs, 
especially treatment-related forms. However, the challenge to repeat biopsies before starting new treatment for 
CRPC is not always feasible and in such cases only elevated serum neuroendocrine markers can facilitate the 
diagnosis of these particular forms of prostate cancer. Our study, which excluded patients with NEPC or small 
cell carcinoma histology and aimed to evaluate the clinical impact of determining circulating NED biomarkers in 
metastatic CRPC patients before a systemic treatment.
Assuming that CgA is a reliable prognostic marker29,30, we divided the patients into different subgroups based 
on pre-therapy CgA levels. Patients treated with abiraterone/enzalutamide post-docetaxel underwent at least 2 
different treatments and showed more elevated serum CgA level than chemotherapy-naïve cases indicating that 
NED is often secondary to androgen deprivation therapy. In addition, higher levels of CgA were observed in 
patients with visceral metastases, especially in the liver, and those with increased LDH values and NLR ≥3. This 
would seem to indicate that association of NED is associated with extent of disease and inflammation in these 
mixed tumor forms, as in NEPC24,31–33.
The primary histology of cases included in this work excluded a neuroendocrine component. However, our 
adenocarcinoma cases had hybrid features with both AR and neuroendocrine markers present and high PSA 
levels. It is possible that these “mixed forms” represent an earlier step of NEPC development nearing the end of an 
AR-dependent state with a paucity of somatic alterations involving the AR gene24. Although a pathological review 
of all included cases would have been useful, especially during treatment, at progression and/or during follow-up; 
the majority of patients did not undergo further biopsy.
The present study confirmed the prognostic impact of higher CgA levels on PFS and OS and the lack of an 
association between CgA concentration and PSA response, as reported in other works28–30,34. We used CgA lev-
els > 3-fold the UNV as the best cut-off to identify a poorer prognostic group, whereas CgA levels > 5-fold the 
UNV35,36 did not provide robust evidence, probably because of the number of patients in the different groups was 
not well-balanced in terms of AR status.
Interestingly, we correlated, for the first time, survival data with the presence of cell-free AR aberrations and 
serum CgA levels, suggesting that the presence of elevated CgA concentration could identify CRPC patients at 
high-risk of developing NEPC and resistance to AR-signalling inhibitors.
Our multivariable analysis confirmed baseline CgA as an independent predictor of survival and further high-
lighted the usefulness of AR CN12–17 and LDH37 as prognostic markers.
Figure 2. Survival in patients treated with abiraterone or enzalutamide by AR status and CgA levels in the 
Secondary cohort. PFS (A) and OS (B) in AR-normal and PFS (C) and OS (D) in AR-gained patients according 
to three different CgA level groups. The blue line is for patients with serum CGA <120 ng/mL, the orange line 
for CGA between 120 and 360 ng/mL, and the green line for CGA level >360 ng/mL.
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The limitations of this study were its retrospective design, small number of patients included in the different 
CgA prognostic groups and high number of previous treatments that influenced the homogeneity of results. 
Moreover, the characteristics of the 2 patient cohorts38 differed slightly but with an uncertain clinical impact (the 
secondary cohort had a higher number of chemotherapy-naïve patients and a shorter median follow-up period 
than the primary cohort). A major limitation of this study was the lack of data on AR splice variants19, as a poten-
tial alternative mechanism of therapeutic resistance.
Genome wide DNA sequencing could also be used to study other molecular mechanisms that may lead to the 
progression of CRPC to NEPC, an effort to define a molecular phenotype of mixed forms between prostate ade-
nocarcinoma and NEPC in association with CgA levels. These include loss of tumor suppressors, such as RB1 and 
p5324,39,40, and amplification of MYCN24. In addition, the study of non-genomic factors such as PEG1041, splicing 
factors like SSRM442,43, and AKT activation overexpression of the master neural transcription factor BRN244 
could contribute to better determining these tumors from a genomic point of view.
Given that germline mutations of DNA repair–deficient prostate cancer have been associated with resistance 
to abiraterone and enzalutamide38 and that these alterations were recently linked with NED molecular pathways 
sharing common platinum-sensitivity45, mixed forms between prostate adenocarcinoma and NEPC could be also 
characterized on the basis of a deficit in DNA damage repair, especially in aggressive CRPC variants with AR CN 
normal.
In conclusion, the evaluation of serum CgA could be key in improving the management of CRPC patients 
displaying a mixed tumor form between adenocarcinoma and NEPC and treated with standard therapies. Given 
that these hubris tumors may retain active AR expression and/or signalling, 2 therapeutic options for this patient 
subgroup could be platinum-based chemotherapy. A combined therapeutic strategy including hormonal drugs 
and other chemotherapeutic agents or targeted therapies (such as aurora kinase inhibitors24 or BRN244) is proba-
bly needed to overcome resistance related to the onset of CgA-expressing clones.
There is now sufficient evidence to warrant carrying out clinical trials that prospectively select treatment on 
the basis of baseline NED markers such as CgA and molecular alterations that drive progression towards NED 
phenotype. Further studies may provide a robust evidence for a change of clinical care for this distinct tumor 
subclass.
Methods
Patients. We collected pre-treatment plasma samples of 256 patients enrolled in 2 biomarkers studies 
approved by the Institutional Review Board of Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori 
(IRST) IRCCS, Meldola, Italy. We selected 197 CRPC patients of the primary cohort between March 2013 and 
July 2015, and 59 patients of the secondary cohort between March 2015 and March 2017. All patients had his-
tology of prostate adenocarcinoma without NED and a progressive disease despite “castration levels” of serum 
testosterone (<50 ng/dL), ongoing LHRH analogue treatment or prior surgical castration. Additional eligibility 
criteria included an Eastern Cooperative Oncology Group (ECOG) performance status 0–2, adequate cardiac, 
renal, hepatic and bone marrow function. Exclusion criteria were renal insufficiency and/or concomitant therapy 
with proton pump inhibitors, which could influence the CgA levels46.
Treatment consisted of anti-AR therapies including abiraterone 1 g once a day and prednisone 5 mg twice 
daily, or enzalutamide 160 mg once a day, in either as pre- or post-chemotherapy setting. The choice of therapy 
was at the discretion of the treating physician. Therapies were administered continuously until there was evidence 
of disease progression or unacceptable toxicity. The studies were conducted in accordance with the Declaration 
of Helsinki and the Good Clinical Practice guidelines of the International Conference of Harmonization. Written 
informed consent was obtained from all patients.
Procedures. Serum CgA levels were measured in duplicate using a two-sided “sandwich” technique with 
two selected antibodies that bind to different epitopes of human CgA (Epitope Diagnostics, Inc - EDI Human 
Chromogranin A ELISA Kit, San Diego, CA), in accordance with the manufacturer’s instructions. The sensitivity 
was 2 mg/L. The inter-assay coefficients of variation of CgA assay were 7.3% and 3.1%. The normal range reported 
by the kit for CgA was 0–120 ng/mL.
All patients underwent a history evaluation and physical examination, and blood tests including complete 
blood cell count, serum PSA, alkaline phosphatase (ALP), and LDH the week before each treatment cycle. PSA 
and blood tests were performed on a monthly basis. Serum CgA levels were determined at baseline and upon 
disease progression. Radiographic evaluation was performed by computed tomography and bone scan at the 
time of screening and every 12 weeks thereafter. Response was evaluated according to Prostate Cancer Working 
Group (PCWG2) guidelines47 and soft tissue disease was assessed using Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1. Peripheral blood samples were collected within 30 days of the start of treatment 
and plasma aliquots were stored at −80 °C. Circulating DNA was extracted from one to two mL of plasma with 
the QIAamp Circulating Nucleic Acid Kit (Qiagen). Total extracted plasma DNA was quantified by 2 methods for 
a major accuracy: spectrophotometric evaluation (NanoDrop® ND-1000, Celbio, Milan, Italy) and Quant-iT high 
sensitivity PicoGreen double-stranded DNA Assay Kit (Invitrogen) for maximum accuracy. AR aberrations [CN 
and somatic point mutations: 2105 T > A (p.L702H) and 2632 A > G (p.T878A) with a limit of detection of 1–2% 
using an input of 2 to 4 ng of DNA] were detected by multiplex ddPCR on a QX200 ddPCR system (Bio-Rad)12–14.
For AR CN analyses, we used the AR gene and at least two different reference genes: RNaseP, NSUN3, ElF2C1, 
and AP3B1 and ZXDB at Xp11.21 as a control gene.
Statistical analysis. The primary endpoint of this study was the association between circulating AR aber-
rations and CgA levels. The secondary endpoints were PFS/OS and PSA response rate (RR) (>50% PSA decline 
after 12 weeks of treatment) stratified by circulating AR status and CgA level.
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Data were summarized by frequency for categorical variables and by median and range for continuous var-
iables. The Wilcoxon rank sum test was performed to compare continuous variables and Chi-Square or Fisher’s 
exact test were performed to compare categorical variables, as appropriate. The cut-offs for CgA in response to 
therapies were determined through ROC curve analysis, as previously reported28,29. Consequently, all patients 
were subdivided into three groups: (1) normal serum CgA level < 120 ng/mL, (2) < 3-fold the UNV 120–360 ng/
mL, and (3) > 3-fold the UNV > 360 ng/mL). In the exploratory sub-analysis, we also used 5-fold the UNV to 
evaluate a potentially more stringent cut-off.
PSA response was considered as a ≥50% decline after a minimum of 12 weeks treatment confirmed by a sec-
ond PSA test after a minimum of four weeks. PFS was calculated from the start of each therapy until the first date 
of progression, death from any cause, or last tumor evaluation. OS was calculated from the start of each therapy 
until death or last follow-up. Survival curves were estimated by the Kaplan-Meier method and were compared 
using the log-rank test. Univariate and multivariate Cox regression models were used to investigate potential 
predictors of PFS and OS and to estimate HR and their 95% CI. For these analyses, we included different clinically 
relevant factors as covariates for both cohorts (age, cell-free AR CN, CgA level, chemotherapy status, number 
of previous treatment lines, Gleason score, site of metastasis, and baseline serum LDH and PSA levels). We also 
conducted landmark analysis to reduce the potential for time-dependent confounding in treatment by assessing 
the impact of changes in serum CgA level from baseline to progression on survival outcome.
All P-values were two-sided and a p < 0.05 was considered as statistically significant. Statistical analyses were 
performed with SAS software version 9.4 (SAS Institute, Cary, NC, USA).
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